Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 15/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 14/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 12/20 | 0.59 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8474094 | 0.99 | ADRA1A (0.58) | ADRA1AADRA1BADRA1DHTR1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL7836707 | 0.99 | ADRA1A (0.58) | ADRA1AADRA1BADRA1DHTR1ASLC6A2 | |
| SCHEMBL6777684 | 0.89 | ADRA1D (0.48) | ADRA1AADRA1BADRA1DHTR1ASLC6A2 | |
| SCHEMBL7821267 | 0.86 | ADRA1D (0.46) | ADRA1AADRA1BADRA1DHTR1ASLC6A2 | |
| SCHEMBL7830587 | 0.85 | HTR3E (0.51) | ADRA1AADRA1BADRA1DHTR1ASLC6A2 | |
| SCHEMBL7830344 | 0.85 | ADRA1A (0.45) | ADRA1AADRA1BADRA1DHTR1ASLC6A2 | |
| SCHEMBL7821743 | 0.85 | HTR1A (0.49) | ADRA1AADRA1BADRA1DHTR1ASLC6A4 | |
| SCHEMBL5473619 | 0.84 | SLC6A2 (0.62) | ADRA1AADRA1BADRA1DHTR1ASLC6A2 | |
| Bromide SCHEMBL7840522 | 0.84 | ADRA1A (0.44) | ADRA1AADRA1BADRA1DHTR1ASLC6A2 | |
| SCHEMBL6194097 | 0.83 | SLC6A2 (0.52) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841682-B2 | Heterocycles useful in the treatment of benign prostatic hyperplasia | JANSEEN PHARMACEUTICA N.V. (BE) | 2005-01-11 | — | — | US | disclosed |
| EP-1273572-B1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | ORTHO MCNEIL PHARM INC (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6680319-B2 | TREATMENT OF OBSTRUCTIVE SYNDROMES OF THE LOWER URINARY TRACT, INCLUDING BENIGN PROSTATIC HYPERPLASIA, TREATMENT OF LOWER URINARY TRACT SYMPTOMS | RECORDATI S.A. (CH) | 2004-01-20 | — | — | US | disclosed |
| EP-1226131-B1 | ISOXAZOLECARBOXAMIDE DERIVATIVES | RECORDATI CHEM PHARM (IT) | 2003-12-17 | — | — | EP | disclosed |
| EP-1200445-B1 | THIENOPYRANECARBOXAMIDE DERIVATIVES | RECORDATI CHEM PHARM (IT) | 2003-09-17 | — | — | EP | disclosed |
| EP-1222183-B1 | BENZOPYRAN DERIVATIVES | RECORDATI CHEM PHARM (IT) | 2003-04-23 | — | — | EP | disclosed |
| EP-1273572-A1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMOANY | 2002-12-19 | — | — | US | disclosed |
| US-20020193381-A1 | Thienopyranecarboxamide derivatives | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-12-19 | — | — | US | disclosed |
| US-6486163-B1 | Thienopyranecarboxamide derivatives | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-11-26 | — | — | US | disclosed |
| US-6365591-B1 | FOR THERAPY OF OBSTRUCTIVE SYNDROMES OF THE LOWER URINARY TRACT, INCLUDING BENIGN PROSTATIC HYPERPLASIA (BPH), AND IN THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS (LUTS) AND NEUROGENIC LOWER URINARY TRACT DYSFUNCTION (NLUTD) | RECORDATI, S.A., CHEMICAL AND PHARMACUETICALS COMPANY (CH) | 2002-04-02 | — | — | US | disclosed |
| US-6306861-B1 | ANTISPASMODIC AGENTS AND TREATMENT OF INCONSTANCE | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2001-10-23 | — | — | US | disclosed |
| EP-0748800-B1 | Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-05-09 | — | — | EP | disclosed |
| WO-2001029022-A1 | BENZOPYRAN DERIVATIVES | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029015-A2 | ISOXAZOLECARBOXAMIDE DERIVATIVES AS ALPHA1-ADRENERGIC RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001009140-A1 | THIENOPYRANECARBOXAMIDE DERIVATIVES | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2001-02-08 | — | — | WO | disclosed |
| EP-1025085-A1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999019299-A1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | NLN, GLS, CPT1B | ADRA1A 525/4885ADRA1B 508/4885ADRA1D 353/4885 |
| US-20020193381-A1 | Thienopyranecarboxamide derivatives | ADRA1D, ADRB3, OPRD1 | ADRA1A 28/4885ADRA1B 37/4885ADRA1D 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.